ITGA6 and breast neoplasm: Nano-targeted delivery of PTC 209 (PLGA-PEG conjugated with anti-CD49f and encapsulating PTC 209) administered daily at 1 mg/Kg, subcutaneously for 2 weeks, demonstrated distinct suppression of breast tumor growth (**P <0.01) as compared to free PTC 209 or PLGA-PEG NPs encapsulated with PTC209 (Figure 8).